Genentech, part of Roche Group (USOTC:RHHBY), has received FDA approval for Tecentriq in combination with chemotherapy for a ...

– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...

Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and other advocacy partners.&nb | "About Damn Time" focuses on the journey ...

Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III ...

Genentech licenses Alector's experimental AL050 program, with another $1.17 billion tied to milestones, plus sales royalties. - ...

Alector will receive $100 million upfront and could earn up to $1. 17 billion in additional milestones while Genentech ...

Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Alector Inc. ( ALEC ), a biopharmaceutical company, on Monday announced that it has entered into an exclusive global licensing agreement with Genentech for its AL050 program. The company will receive ...

The agreement sets licensed launch dates for Biocon’s pertuzumab biosimilar in the EU, UK, US and other markets ...